An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesilate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) in Smoking and Non-Smoking Adult Volunteers.

Trial Profile

An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesilate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) in Smoking and Non-Smoking Adult Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics; Registrational
  • Sponsors Allergan
  • Most Recent Events

    • 05 Jun 2011 Results presented at the 53rd Annual Scientific Meeting of the American Headache Society.
    • 28 Feb 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN).
    • 27 Sep 2010 Actual initiation date changed from 16 Feb 2010 to 1 Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top